# Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses

> **NCT02816151** · PHASE3 · COMPLETED · sponsor: **CHU de Reims** · enrollment: 29 (actual)

## Conditions studied

- Neurogenic Vesical Hyperactivity Syndrom

## Interventions

- **DRUG:** full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox
- **DRUG:** half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox

## Key facts

- **NCT ID:** NCT02816151
- **Lead sponsor:** CHU de Reims
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02816151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02816151, "Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02816151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*